Amphastar Pharmaceuticals (NASDAQ:AMPH) Given New $32.00 Price Target at Piper Sandler

Amphastar Pharmaceuticals (NASDAQ:AMPH) had its price objective reduced by Piper Sandler from $36.00 to $32.00 in a research report sent to investors on Friday,Benzinga reports. Piper Sandler currently has a neutral rating on the stock.

Separately, Wells Fargo & Company started coverage on shares of Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 target price for the company.

Amphastar Pharmaceuticals Price Performance

Shares of AMPH opened at $28.29 on Friday. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals has a twelve month low of $25.89 and a twelve month high of $53.96. The stock has a market capitalization of $1.35 billion, a P/E ratio of 9.43, a P/E/G ratio of 2.19 and a beta of 0.77. The company has a 50 day moving average of $31.91 and a 200-day moving average of $40.48.

Insider Activity

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the transaction, the chief financial officer now owns 97,363 shares of the company’s stock, valued at $2,681,377.02. The trade was a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 27.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Smartleaf Asset Management LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 222.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock worth $26,000 after buying an additional 493 shares during the period. Parkside Financial Bank & Trust raised its stake in Amphastar Pharmaceuticals by 806.5% in the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company’s stock worth $36,000 after purchasing an additional 871 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in Amphastar Pharmaceuticals in the 4th quarter valued at about $38,000. Tower Research Capital LLC TRC grew its position in shares of Amphastar Pharmaceuticals by 43.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company’s stock worth $43,000 after purchasing an additional 348 shares in the last quarter. Finally, Huntington National Bank increased its holdings in shares of Amphastar Pharmaceuticals by 36.9% during the fourth quarter. Huntington National Bank now owns 1,340 shares of the company’s stock worth $50,000 after purchasing an additional 361 shares during the period. 65.09% of the stock is currently owned by institutional investors.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.